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Original Articles 
Long-term oxygen therapy may improve skeletal 
muscle metabolism in advanced chronic obstructive 
pulmonary disease patients with chronic hypoxaemia 
P. JAKOBSSON* AND L. JORFELDT~ 
*Department of Pulmonary Medicine, University Hospital, Linkiiping, and TDepartment of Thoracic 
Physiology, Karolinska Hospital, Stockholm, Sweden 
Skeletal muscle metabolite depletion exists in advanced chronic obstructive pulmonary disease (COPD) 
patients with chronic hypoxaemia. The purpose of this study was to investigate if long-term oxygen therapy 
(LTOT) can improve skeletal muscle energy metabolism. Eight patients with advanced COPD, four with 
chronic hypoxaemia, were investigated using muscle biopsy specimens from the quadriceps femoris muscle 
applying the needle biopsy technique. The investigation was performed twice, before and after approximately 
8 months of LTOT in the hypoxaemic patients. Eight healthy controls of similar age were also investigated. 
In the COPD patients, muscle glycogen, ATP and creatine phosphate (CrP) concentrations, were 42% 
(P<O.Ol), 18% (PcO.05) and 21% (P=n.s.) lower than in the healthy controls, respectively, while creatine (Cr) 
and lactate concentrations were 21% and 90% higher, respectively in the COPD patients compared to the 
healthy control subjects (PcO.05). After LTOT, the ‘energy index’ CrP/(CrP+Cr) ratio increased by 0.12 in 
the LTOT patients but decreased by 0.12 in the control COPD patients (P~0.05). The results indicate an 
improvement in skeletal muscle energy metabolism during LTOT in COPD patients with chronic hypoxaemia. 
Introduction 
Studies of chronic obstructive pulmonary disease 
(COPD) patients have demonstrated deterioration in 
muscle metabolism not only in respiratory, but also 
in non-respiratory muscles such as the quadriceps 
femoris (1,2). We have reported low concentrations 
of glycogen, creatine phosphate (CrP) and ATP in 
patients with COPD and respiratory failure, a very 
low percentage of ‘oxidative’ Type I muscle fibres (3), 
and results of metabolic enzyme activity analyses 
indicating adaptation in the form of augmented 
glycolysis and decreased aerobic metabolism (4) in 
the quadriceps femoris muscle in advanced COPD. 
Furthermore, significant correlations between muscle 
glycogen, CrP, creatine (Cr) and percentage of Type 
I fibres vs. arterial PO, have been found (3) which 
may support the hypothesis that hypoxaemia is a 
factor of importance in the metabolic deterioration 
process. In COPD patients with chronic hypoxaemia, 
long-term oxygen therapy (LTOT) improves survival 
(.5,6), exercise performance (7,8), can stabilize or 
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reverse pulmonary hypertension (9,lO) and reduce 
haematocrit (5). A study using the magnetic reso- 
nance spectroscopy (MRS) technique has shown that 
oxygen supplementation in hypoxaemic COPD 
patients can also result in biochemical changes in 
non-respiratory skeletal muscle (11). 
The aim of the present study was to test the 
hypothesis that LTOT has a beneficial effect on 
skeletal muscle metabolism in the clinical situation 
where oxygen treatment is administered to COPD 
patients at home over a long period of time, and 
where metabolites are assessed using biochemical 
analysis of biopsy specimens. 
Subjects and Methods 
SUBJECTS 
Three men and five women with advanced COPD 
attending the lung medicine department (Linkoping) 
as outpatients were investigated. The criteria for 
inclusion were a stable clinical status with no sign of 
infection. Patients with known malignancy, hepatic, 
metabolic and renal disease, and left ventricular 
failure were excluded from this study. 
In four of the COPD patients, LTOT was started 
because of chronic hypoxaemia (LTOT group). 
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These patients were investigated twice. The first 
investigation was performed prior to the start of 
LTOT and the second investigation was performed 
after 69 months of treatment (Investigations 1 and 2 
respectively). The criteria, at our department, for 
starting oxygen therapy at home are COPD in a 
clinically stable state, on optimal therapy and arterial 
PO,<8 kPa at rest, breathing air. Oxygen was pre- 
scribed for at least 16 h day - ‘, and the aim was to 
reach 29 kPa (67.5 mmHg) at rest. 
Two control groups were investigated: (1) the 
COPD patients not receiving LTOT, (COPD-C 
group) who were also investigated twice, with 6-9 
months between Investigations 1 and 2; and (2) a 
healthy control group (HC group) investigated once, 
comprising eight sedentary subjects similar in age to 
the COPD patients, five men and three women, 
without any known disease and not taking any 
medication. 
All patients were receiving pharmacological treat- 
ment as follows: six patients oral theophylline, all 
patients a &-agonist for inhalation on a regular 
on-demand basis or an oral &agonist, five patients 
an anti-cholinergic bronchodilator for inhalation, 
five patients an inhalational steroid, two patients an 
oral steroid, two patients a diuretic, one patient an 
angiotensin converting enzyme (ACE) inhibitor and 
six patients oral acetylcysteine. 
The patients were examined regularly during the 
study period at our department including arterial 
blood gas values when breathing air as well as with 
supplemental oxygen flow. Furthermore, the patients 
were asked about their treatment at regular intervals 
to find out about any problems and to ensure that the 
patients used the extra oxygen as prescribed. Oxygen 
was administered from concentrators in the patients’ 
homes and from small gas cylinders for use when 
outside. 
Informed consent was obtained and the study was 
approved by the local Ethics Committee. 
PROCEDURE AND ANALYSIS 
After an overnight fast and while breathing room 
air, muscle biopsy specimens from the lateral part of 
the quadriceps femoris muscle, approximately 10 cm 
above the patella, were obtained by means of the 
needle biopsy technique (12). The biopsies were 
frozen in liquid nitrogen immediately after with- 
drawal and stored at - 80°C or less pending subse- 
quent analysis. The biopsies were freeze-dried and 
blood, fat and connective tissue were carefully 
removed by manual dissection. The tissue was then 
powderly extracted with perchloric acid, and neutral- 
ized with KCO,. The extract was analysed for 
ATP, CrP, Cr, and lactate content (13). Analysis of 
glycogen was performed on a second portion of the 
dissected tissues (14). 
Arterial blood samples were drawn from the radial 
artery, for analysis of blood gas values. All patients 
and control subjects were investigated with measure- 
ment of dynamic lung volumes. The percentage of 
ideal body weight (IBW) for each subject’s height 
and sex was calculated using a Swedish standard 
table (15). 
PRESENTATION OF DATA AND THE STATISTICAL 
METHODS 
The results are expressed as mean * SEM. For 
comparisons between groups, the Mann-Whitney 
U-test was used. Non-parametric statistics were 
also used for comparison of differences in arterial 
blood gas values whilst breathing air and with 
supplemental oxygen. PcO.05 was accepted as 
significant. 
Results 
Characteristics of the COPD patients and the 
healthy controls (HC group) are summarized in Table 
1. Characteristics of the oxygen-treated COPD pa- 
tients (LTOT group) and the COPD patients 
studied as a control group (COPD-C group) are sum- 
marized in Table 2. The interval between Investiga- 
tions 1 and 2 was 239 f 36 and 254 f 28 days in the 
LTOT and COPD-C groups respectively (P=n.s.). At 
the time of Investigation 2, arterial PO, (breathing 
room air) had increased in the LTOT group 
but decreased in the COPD-C group compared to 
Investigation 1. The difference between Investigations 
2 and 1 was +0.7 f 0.2 kPa (5.3 & 1.5 mmHg) 
and - 0.9 f 0.6 kPa (6.8 f 4.5 mmHg) (P=O.O2) 
in the LTOT and COPD-C groups, respectively. 
The corresponding differences for arterial PCO, 
were +0.2 i 0.3 kPa (+ 1.5 f 2.3 mmHg) and 
- 0.1 % 0.1 kPa ( - 0.8 f. 0.8 mmHg) (P=n.s.) in the 
LTOT and COPD-C groups, respectively. The 
oxygen flow prescribed at the start of treatment was 
2.2*0.51min-‘. The difference in arterial PO, with 
and without prescribed oxygen flow in the LTOT 
group was + 2.4 + 0.9 kPa (18.0 f 6.8 mmHg) 
(P=n.s.) and +2.6 & 0.8 kPa (19.5 f 6.0 mmHg) 
(P=n.s.) at the beginning and at the end of the 
investigation period, respectively. For arterial PCO,, 
the corresponding figures were +0.2 * 0.1 kPa 
(1.5 & 0.8 mmHg) (P=n.s.) and 0.1 & 0.1 kPa 
(0.8 & 0.8 mmHg) (P=n.s.), respectively, and for oxy- 
gen saturation +5.0 f 1.2% (P=n.s.) and 
+5.0 * 1.2% (P=n.s.), respectively. 
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Table I Characteristics of the COPD patients (COPD group) and the healthy control subjects 
WC grow) 
COPD group (n=8) HC group (n=8) 
mean SEM mean SEM P value 
Male/female 315 
Age (years) 63.2 
Height (cm) 163.9 
Weight (kg) 63.8 
Ideal body weight (%) 91.7 
FEV, (1) 0.7 
FEV, (% predicted) 28.0 
FVC (1) 2.0 
FVC (% predicted) 57.1 
FEVJFVC 0.36 
P,02 (kPa) 7.8 
[mm%1 [58.5] 
P,CO, (kPa) 5.7 
bmHs1 [42.7] 
3.6 
4.0 
7.7 
6.8 
0.1 
3.1 
0.3 
5.1 
0.03 
0.7 
l5.21 
0.3 
12.21 
513 
65.5 
171.7 
78.8 
105.8 
2.8 
101.8 
3.9 
95.6 
0.72 
11.4 
[85.5] 
5.2 
[39.0] 
1.3 
3.0 
4.2 
3.8 
0.1 
4.0 
0.2 
2.5 
0.02 
0.5 
l3.71 
0.1 
IO.71 
0.52 
0.15 
0.14 
0.15 
0.0008 
0.0008 
0.002 
0.0008 
0.0008 
0.004 
0.14 
Table 2 Characteristics of the oxygen-treated COPD patients (LTOT group) and the COPD 
control patients (COPD-C group) 
LTOT group (n=4) COPD-C group (n=4) 
mean SEM mean SEM P value 
Male/female 212 113 
Age (years) 61.2 2.9 65.2 7.0 0.38 
Height (cm) 167.6 6.4 160.2 5.0 0.38 
Weight (kg) 71.9 13.3 55.6 7.5 0.38 
Ideal body weight (%) 97.9 10.7 85.5 8.8 0.24 
FEV, (1) 0.8 0.1 0.6 0.1 0.24 
FEV, (% predicted) 27.7 2.4 28.2 6.2 0.88 
FVC (1) 2.6 0.4 1.5 0.2 0.08 
FVC (% predicted) 67.7 4.4 46.5 5.3 0.04 
FEVJFVC 0.30 0.02 0.43 0.04 0.08 
Pa02 W’a) 6.2 0.2 9.4 0.7 0.02 
bmHg1 [46.5] Il.51 [70,5] ~5.21 
P,CO, (kPa) 5.7 0.6 5.6 o-2 0.38 
[mmHsl [42.7] L4.51 [42.0] Il.51 
Muscle glycogen and ATP in the COPD group 
were significantly lower than in the HC group 
(PcO.01 and PcO.05, respectively). Creatine phos- 
phate was lower in the COPD group than in the HC 
group, although it did not reach statistical signifi- 
cance (P<O.l). Creatine and lactate concentrations 
were higher in the COPD group than in the HC 
group (PcO.05). The CrP/(CrP+Cr) ratio was signifi- 
cantly lower in the COPD group compared to the HC 
group (P-=0.05) (Table 3). 
The metabolite concentrations obtained at Investi- 
gation 1 and Investigation 2 for the LTOT and 
COPD-C groups are summarized in Table 4. The 
increase in CrP during LTOT treatment in the LTOT 
group was 21.8 mmol kg - ’ dry muscle (d.m.) (49%) 
compared to a decrease of 13.9 mmol kg- ’ d.m. 
(25%) in the COPD-C group (P=O.OS). In the LTOT 
group, there was a 5% decrease in Cr compared to an 
increase of 27% in the COPD-C group (3.7 and 
15.6 mmol kg- ’ d.m., respectively) (P=O.O2). The 
effect of LTOT on muscle metabolism is also illus- 
trated by the CrP/(CrP+Cr) ratio which increased by 
0.12 in the oxygen-treated group during the study 
period and decreased by 0.12 in the COPD group 
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Table 3 Concentrations of skeletal muscle metabolites and skeletal muscle ‘energy index’ 
[CrP/(CrP+Cr)] in the COPD patients (COPD group) and in the healthy control subjects (HC 
group) 
COPD group (n=8) HC group (n=8) 
mean SEM mean SEM P value 
Glycogen 234 24 
(mmol glycosyl units kg- ’ d.m.) 
ATP (mmol kg- ’ d.m.) 17.5 1.2 
CrP (mmol kg- ’ d.m.) 49.4 6.4 
Cr (mmol kg- ’ d.m.) 60.7 2.4 
CrP+Cr (mmol kg- ’ d.m.) 110.1 7.0 
CrP/(CrP+ Cr) 0.43 0.03 
Lactate (mmol kg- ’ d.m.) 4.2 0.9 
CrP, creatine phosphate; Cr, creatine; d.m., dry muscle. 
407 38 0.002 
21.5 0.7 0.02 
62.9 3.6 0.09 
49.9 3.2 0.02 
112.9 2.8 0.8 
0.55 0.02 0.03 
2.2 0.3 0.04 
Table 4 Concentrations of skeletal muscle metabolites and skeletal muscle ‘energy index’ [CrP/(CrP+Cr)] at start and after 
approximately 8 months of long-term oxygen therapy in four hypoxaemic COPD patients (LTOT group) and in four COPD 
control subjects (COPD-C group) 
LTOT group (n =4) COPD-C group (n=4) 
Investigation 1 Investigation 2 Investigation 1 Investigation 2 
mean SEM mean SEM mean SEM mean SEM P value* 
Glycogen 233 35 
(mmol glycosyl units kg ’ d.m.) 
271 55 236 40 235 30 0.72 
ATP (mmol kg - ’ d.m.) 16.3 1.7 19.1 0.6 18.6 1.8 18.5 1.7 0.56 
CrP (mmol kg- ’ d.m.) 44.1 7.6 65.9 7.8 54.6 10.7 40.7 4.4 0.08 
Cr (mmol kg- ’ d.m.) 65.0 2.2 61.3 6.4 56.4 3.2 72.0 3.5 0.02 
CrP+Cr (mmol kg-’ d.m.) 109.1 9.8 127.3 6.5 111.1 11.6 112.8 7.6 0.56 
CrP/(CrP+Cr) 0.39 0.03 0.51 0.05 0.47 0.05 0.35 0.01 0.04 
Lactate (mmol kg - ’ d.m.) 5.6 1.5 4.3 1.9 2.9 0.5 6.3 1.6 0.14 
*From comparisons between the LTOT and COPD-C groups of the differences between Investigation 1 and Investigation 
2 in both groups. CrP, creatine phosphate; Cr, creatine; d.m., dry muscle. 
(P=O.O4). Changes in metabolite concentrations 
between Investigations 1 and 2 were not significantly 
different between the LTOT and COPD-C groups for 
muscle glycogen, ATP and lactate. 
Discussion 
In COPD patients with chronic hypoxaemia, 
LTOT improves survival (5,6), exercise performance 
(7,8), can stabilize or reverse pulmonary hypertension 
(9,lO) and reduce haematocrit (5). The present study 
suggests that LTOT can also improve the skeletal 
muscle energy situation. 
This paper reports the effect of LTOT on skeletal 
muscle high-energy phosphate metabolism which is 
illustrated by the ‘energy index’ CrP/(CrP+Cr) ratio 
which increased 30% in the oxygen-treated group 
during the study period, and decreased 25% in the 
COPD control group. This index has the advantage 
of being relatively insensitive to the quality of the 
biopsy. The atrophy of skeletal muscle seen in 
severe COPD (1) reduces the quality of biopsy speci- 
mens and could theoretically have influenced the 
analyses even when - as in this study-the freeze- 
dried material was carefully dissected before analysis. 
Energy for muscle contraction is supplied by the 
hydrolysis of ATP to ADP. ATP is mainly regener- 
ated by mitochondrial oxidative phosphorylation. 
In addition, the phosphate group of CrP can be 
transferred to ADP to form ATP. 
CrP+ADP+H+ <=> Cr+ATP 
This reaction is reversible and near to equilibrium 
in vivo - CrP acting as an energy buffer. 
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ATP and CrP concentrations in peripheral skeletal 
muscle are low in COPD patients with chronic 
hypoxaemia (3), in the present study 24 and 29% 
lower respectively than in the healthy controls. An 
increase in ‘energy index’, as reported here, may 
reflect improvement in oxidative phosphorylation as 
a result of an increase in oxygen delivery to the 
muscle cell as a result of LTOT. 
In this study, arterial PO, (breathing room air) was 
higher in the LTOT group after 8 months of oxygen 
therapy than at the start. In the control COPD 
group, arterial PO, decreased over the same time 
period. Stabilization of arterial blood gas values 
occurs in some oxygen-treated COPD patients and 
is associated with increased survival (6). Long-term 
oxygen therapy and the improvement in arterial 
PO, (breathing room air) seen in all four oxygen- 
treated COPD patients might have contributed, as 
a result of increased peripheral oxygenation, to 
the improvement in skeletal muscle metabolite 
content. This hypothesis is supported by the study 
of Payen et al. using the MRS technique (11). 
They recently reported that acute correction of 
hypoxaemia in COPD patients with chronic 
hypoxaemia resulted in biochemical changes in leg 
muscle during and after exercise. Hence, the P,/CrP 
ratio decreased, intracellular pH increased and the 
resynthesis rate of CrP became faster during oxygen 
supplementation. The authors suggest that this is the 
result of improvement in ATP synthesis from oxida- 
tive phosphorylation and reduction in the require- 
ment of anaerobic metabolism while on oxygen 
supplementation. 
To our knowledge, no study on the effect of 
remobilization after a period of immobilization on 
skeletal muscle metabolism in COPD patients has 
been reported. Although our patients did not take 
part in any physical activity programme, it is not 
possible from our results to state whether the 
improvement is an effect of increased oxygen delivery 
in the peripheral skeletal muscle or an effect of 
increased physical activity observed in hypoxaemic 
COPD patients during LTOT, or both. 
Arterial PO, in the LTOT and COPD-C groups 
differed. From an ethical point of view, it was not 
possible to choose a control group with severe 
hypoxaemia. This difference in arterial PO, might 
have influenced the results. Furthermore, although 
both groups had severe obstructive disease, predicted 
FVC % was significantly lower in the COPD-C group 
compared to the LTOT group, and the possibility 
that the COPD-C and LTOT groups represent two 
different subgroups of COPD patients cannot be 
excluded. 
Patients in both the LTOT and COPD-C groups 
were treated with medications. It was not possible 
from an ethical point of view to withdraw medication 
in these severely-ill patients. We cannot exclude the 
possibility that treatment influenced the metabolic 
state. If this is the case, however, the same influence 
has been exerted in both groups. 
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